New immunotherapy combo aims to fight advanced kidney cancer

NCT ID NCT07159191

Not yet recruiting Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a combination of two drugs—envafolimab (an immunotherapy injection) and axitinib (a targeted therapy pill)—as a first treatment for people with advanced kidney cancer that has spread or cannot be removed. About 30 participants will receive the treatment for up to 2 years. Researchers will measure how well the drugs shrink tumors and control the cancer, while closely monitoring side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Envafolimab (immunotherapy injection) and Axitinib (targeted therapy pill)
What this could lead to: If successful, this combination could offer a new first-line treatment option for advanced kidney cancer, potentially shrinking tumors and delaying disease progression.
What could go wrong: This is a small, early-phase (Phase 2) study with only 30 participants and no comparison group. The treatment may cause side effects like immune reactions or high blood pressure, and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED RENAL CELL CARCINOMA (ARCC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.